34 research outputs found

    Π ΠΎΠ·Ρ€ΠΎΠ±ΠΊΠ° Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³Ρ–Ρ— ΡƒΡ‚ΠΈΠ»Ρ–Π·Π°Ρ†Ρ–Ρ— ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ–Π² очистки промислових стоків ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ— Ρƒ ΠΌΠ°Ρ‚Ρ€ΠΈΡ†Ρ– Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Ρ–Π²

    Get PDF
    The object of research is liquid and solid wastes resulting from the processing of highly concentrated wastewater from industrial enterprises using the ferritization method. It is known that galvanic production creates large volumes of highly toxic waste requiring further processing or safe disposal. One of the most problematic places is the use of traditional reagent methods that do not provide high rates of treated water and chemical stability of a significant amount of solid-phase waste water.The use of ferritization technology allows eliminating the indicated disadvantages and increasing the efficiency of the industrial wastewater treatment process. In the course of the study, improved ferritization method with electromagnetic activation of the process is used, which can significantly increase its energy efficiency. However, dense and stable ferritization sediments that contain toxic compounds of heavy metals need reliable disposal. But even with proper treatment of wastewater from heavy metal compounds, they contain a large amount of other pollutants, making it impossible to discharge such water into natural water bodies, in particular, because of its increased alkalinity. Environmentally safe use of such substandard products in solid and liquid state as components of building materials is developed. The most effective cementing materials with reliable immobilization of industrial waste compounds are alkaline binders. The performance properties of such modified alkaline cements and concretes based on them are obtained. The leaching of heavy metal ions from the matrix of the material is investigated and their reliable fixation in the structure of alkaline cements is proved. Due to this, immobilization of water treatment products in alkaline cements and concretes based on them does not degrade the performance of their properties and at the same time provides the advantages of such waste disposal.Compared with similar known technologies, a completely waste-free complex treatment of industrial wastes of electroplating plants of industrial enterprises is developed.ΠžΠ±ΡŠΠ΅ΠΊΡ‚ΠΎΠΌ исслСдований ΡΠ²Π»ΡΡŽΡ‚ΡΡ ΠΆΠΈΠ΄ΠΊΠΈΠ΅ ΠΈ Ρ‚Π²Π΅Ρ€Π΄Ρ‹Π΅ ΠΎΡ‚Ρ…ΠΎΠ΄Ρ‹, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ Π² Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π΅ ΠΏΠ΅Ρ€Π΅Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ высококонцСнтрированных сточных Π²ΠΎΠ΄ ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… прСдприятий ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ. Π˜Π·Π²Π΅ΡΡ‚Π½ΠΎ, Ρ‡Ρ‚ΠΎ Π³Π°Π»ΡŒΠ²Π°Π½ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ производства производят большиС ΠΎΠ±ΡŠΠ΅ΠΌΡ‹ высокотоксичных ΠΎΡ‚Ρ…ΠΎΠ΄ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Ρ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ дальнСйшСй ΠΏΠ΅Ρ€Π΅Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ ΠΈΠ»ΠΈ бСзопасного захоронСния. Одним ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ½Ρ‹Ρ… мСст являСтся использованиС Ρ‚Ρ€Π°Π΄ΠΈΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… Ρ€Π΅Π°Π³Π΅Π½Ρ‚Π½Ρ‹Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Π½Π΅ ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‚ высокиС ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ ΠΎΡ‡ΠΈΡ‰Π΅Π½Π½ΠΎΠΉ Π²ΠΎΠ΄Ρ‹ ΠΈ химичСской стойкости Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ количСства Ρ‚Π²Π΅Ρ€Π΄ΠΎΡ„Π°Π·ΠΎΠ²Ρ‹Ρ… ΠΎΡ‚Ρ…ΠΎΠ΄ΠΎΠ² водоочистки.ИспользованиС Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΉ Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ позволяСт ΠΈΠ·Π±Π΅ΠΆΠ°Ρ‚ΡŒ ΡƒΠΊΠ°Π·Π°Π½Π½Ρ‹Ρ… нСдостатков ΠΈ ΡƒΠ»ΡƒΡ‡ΡˆΠΈΡ‚ΡŒ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ процСсса ΠΏΠ΅Ρ€Π΅Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ сточных Π²ΠΎΠ΄. Π’ Ρ…ΠΎΠ΄Π΅ исслСдований использовали ΡƒΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½ΡΡ‚Π²ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ Π°Π²Ρ‚ΠΎΡ€Π°ΠΌΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ с элСктромагнитной Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠ΅ΠΉ процСсса, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΉ позволяСт сущСствСнно ΠΏΠΎΠ²Ρ‹ΡΠΈΡ‚ΡŒ Π΅Π³ΠΎ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ. Однако ΠΏΠ»ΠΎΡ‚Π½Ρ‹Π΅ ΠΈ стойкиС осадки Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ содСрТат токсичныС соСдинСния тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ², Ρ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΡƒΡ‚ΠΈΠ»ΠΈΠ·Π°Ρ†ΠΈΠΈ. Но Π΄Π°ΠΆΠ΅ ΠΏΡ€ΠΈ Π½Π°Π΄Π»Π΅ΠΆΠ°Ρ‰Π΅ΠΉ очисткС сточных Π²ΠΎΠ΄ ΠΎΡ‚ соСдинСний тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ² ΠΎΠ½ΠΈ содСрТат большоС количСство Π΄Ρ€ΡƒΠ³ΠΈΡ… загрязнитСлСй, Ρ‡Ρ‚ΠΎ Π΄Π΅Π»Π°Π΅Ρ‚ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½Ρ‹ΠΌ сброс Ρ‚Π°ΠΊΠΎΠΉ Π²ΠΎΠ΄Ρ‹ Π² ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ‹Π΅ Π²ΠΎΠ΄ΠΎΠ΅ΠΌΡ‹, Π² частности, Π²Π²ΠΈΠ΄Ρƒ Π΅Π΅ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½ΠΎΠΉ щСлочности. Π Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Π° экологичСски бСзопасная тСхнология использования Ρ‚Π°ΠΊΠΈΡ… Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² Π² Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΌ ΠΈ ΠΆΠΈΠ΄ΠΊΠΎΠΌ состоянии ΠΊΠ°ΠΊ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² ΡΡ‚Ρ€ΠΎΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΠΎΠ². НаиболСС эффСктивными Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠΌΠΈ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π°ΠΌΠΈ с Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ соСдинСний тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ² ΡΠ²Π»ΡΡŽΡ‚ΡΡ Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Π΅ вяТущиС вСщСства. Π’ Ρ€Π°Π±ΠΎΡ‚Π΅ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ эксплуатационныС свойства Ρ‚Π°ΠΊΠΈΡ… ΠΌΠΎΠ΄ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Ρ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΠΎΠ² ΠΈ Π±Π΅Ρ‚ΠΎΠ½ΠΎΠ² Π½Π° ΠΈΡ… основС. ИсслСдовано Π²Ρ‹Ρ‰Π΅Π»Π°Ρ‡ΠΈΠ²Π°Π½ΠΈΠ΅ ΠΈΠΎΠ½ΠΎΠ² тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ² ΠΈΠ· ΠΌΠ°Ρ‚Ρ€ΠΈΡ†Ρ‹ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π° ΠΈ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° ΠΈΡ… надСТная фиксация Π² структурС Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Ρ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΠΎΠ². Благодаря этому иммобилизация ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² водоочистки Π² Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Ρ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Π°Ρ… ΠΈ Π±Π΅Ρ‚ΠΎΠ½Π°Ρ… Π½Π° ΠΈΡ… основС Π½Π΅ ΡƒΡ…ΡƒΠ΄ΡˆΠ°Π΅Ρ‚ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ ΠΈΡ… эксплуатационных свойств ΠΈ ΠΏΡ€ΠΈ этом обСспСчиваСт прСимущСства Ρ‚Π°ΠΊΠΎΠΉ ΡƒΡ‚ΠΈΠ»ΠΈΠ·Π°Ρ†ΠΈΠΈ ΠΎΡ‚Ρ…ΠΎΠ΄ΠΎΠ².Π’ сравнСнии с Π°Π½Π°Π»ΠΎΠ³ΠΈΡ‡Π½Ρ‹ΠΌΠΈ извСстными тСхнологиями Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Π° ΠΏΠΎΠ»Π½ΠΎΡΡ‚ΡŒΡŽ бСзотходная тСхнология комплСксной очистки ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… стоков Π³Π°Π»ΡŒΠ²Π°Π½ΠΈΡ‡Π΅ΡΠΊΠΈΡ… производств ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… прСдприятий.Об'Ρ”ΠΊΡ‚ΠΎΠΌ дослідТСння Ρ” Ρ€Ρ–Π΄ΠΊΡ– Ρ‚Π° Ρ‚Π²Π΅Ρ€Π΄Ρ– Π²Ρ–Π΄Ρ…ΠΎΠ΄ΠΈ, які ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π½Ρ– Π² Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ– ΠΏΠ΅Ρ€Π΅Ρ€ΠΎΠ±ΠΊΠΈ висококонцСнтрованих стічних Π²ΠΎΠ΄ промислових підприємств ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ—. Π’Ρ–Π΄ΠΎΠΌΠΎ, Ρ‰ΠΎ Π³Π°Π»ΡŒΠ²Π°Π½Ρ–Ρ‡Π½Ρ– Π²ΠΈΡ€ΠΎΠ±Π½ΠΈΡ†Ρ‚Π²Π° ΡΡ‚Π²ΠΎΡ€ΡŽΡŽΡ‚ΡŒ Π²Π΅Π»ΠΈΠΊΡ– об’єми високотоксичних Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π², які ΠΏΠΎΡ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ΡŒ ΠΏΠΎΠ΄Π°Π»ΡŒΡˆΠΎΡ— ΠΏΠ΅Ρ€Π΅Ρ€ΠΎΠ±ΠΊΠΈ Π°Π±ΠΎ Π±Π΅Π·ΠΏΠ΅Ρ‡Π½ΠΎΠ³ΠΎ захоронСння. Одним Π· Π½Π°ΠΉΠ±Ρ–Π»ΡŒΡˆ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ½ΠΈΡ… ΠΌΡ–ΡΡ†ΡŒ Ρ” застосування Ρ‚Ρ€Π°Π΄ΠΈΡ†Ρ–ΠΉΠ½ΠΈΡ… Ρ€Π΅Π°Π³Π΅Π½Ρ‚Π½ΠΈΡ… ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ–Π², які Π½Π΅ Π·Π°Π±Π΅Π·ΠΏΠ΅Ρ‡ΡƒΡŽΡ‚ΡŒ високих ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡ–Π² ΠΎΡ‡ΠΈΡ‰Π΅Π½ΠΎΡ— Π²ΠΎΠ΄ΠΈ Ρ‚Π° Ρ…Ρ–ΠΌΡ–Ρ‡Π½ΠΎΡ— стійкості Π·Π½Π°Ρ‡Π½ΠΎΡ— ΠΊΡ–Π»ΡŒΠΊΠΎΡΡ‚Ρ– Ρ‚Π²Π΅Ρ€Π΄ΠΎΡ„Π°Π·Π½ΠΈΡ… Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π² водоочищСння.Використання Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–ΠΉΠ½ΠΎΡ— Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³Ρ–Ρ— дозволяє усунути Π·Π°Π·Π½Π°Ρ‡Π΅Π½Ρ– Π½Π΅Π΄ΠΎΠ»Ρ–ΠΊΠΈ Ρ‚Π° ΠΏΠΎΠΊΡ€Π°Ρ‰ΠΈΡ‚ΠΈ Π΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡΡ‚ΡŒ процСсу ΠΏΠ΅Ρ€Π΅Ρ€ΠΎΠ±ΠΊΠΈ промислових стічних Π²ΠΎΠ΄. Π’ Ρ…ΠΎΠ΄Ρ– дослідТСння використовувалися удосконалСний Π°Π²Ρ‚ΠΎΡ€Π°ΠΌΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ— Ρ–Π· Π΅Π»Π΅ΠΊΡ‚Ρ€ΠΎΠΌΠ°Π³Π½Ρ–Ρ‚Π½ΠΎΡŽ Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†Ρ–Ρ”ΡŽ процСсу, Ρ‰ΠΎ дозволяє суттєво ΠΏΡ–Π΄Π²ΠΈΡ‰ΠΈΡ‚ΠΈ ΠΉΠΎΠ³ΠΎ Π΅Π½Π΅Ρ€Π³ΠΎΠ΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡΡ‚ΡŒ. ΠŸΡ€ΠΎΡ‚Π΅ Ρ‰Ρ–Π»ΡŒΠ½Ρ– Ρ– стійкі осади Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ—, які ΠΌΡ–ΡΡ‚ΡΡ‚ΡŒ токсичні сполуки Π²Π°ΠΆΠΊΠΈΡ… ΠΌΠ΅Ρ‚Π°Π»Ρ–Π², ΠΏΠΎΡ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ΡŒ Π½Π°Π΄Ρ–ΠΉΠ½ΠΎΡ— ΡƒΡ‚ΠΈΠ»Ρ–Π·Π°Ρ†Ρ–Ρ—. АлС Π½Π°Π²Ρ–Ρ‚ΡŒ ΠΏΡ€ΠΈ Π½Π°Π»Π΅ΠΆΠ½ΠΎΠΌΡƒ ΠΎΡ‡ΠΈΡ‰Π΅Π½Π½Ρ– стічних Π²ΠΎΠ΄ Π²Ρ–Π΄ сполук Π²Π°ΠΆΠΊΠΈΡ… ΠΌΠ΅Ρ‚Π°Π»Ρ–Π², Π²ΠΎΠ½ΠΈ ΠΌΡ–ΡΡ‚ΡΡ‚ΡŒ Π²Π΅Π»ΠΈΠΊΡƒ ΠΊΡ–Π»ΡŒΠΊΡ–ΡΡ‚ΡŒ Ρ–Π½ΡˆΠΈΡ… Π·Π°Π±Ρ€ΡƒΠ΄Π½ΡŽΠ²Π°Ρ‡Ρ–Π², Ρ‰ΠΎ ΡƒΠ½Π΅ΠΌΠΎΠΆΠ»ΠΈΠ²Π»ΡŽΡ” скидання Ρ‚Π°ΠΊΠΎΡ— Π²ΠΎΠ΄ΠΈ Ρƒ ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ– Π²ΠΎΠ΄ΠΎΠΉΠΌΠΈ, Π·ΠΎΠΊΡ€Π΅ΠΌΠ°, Ρ‡Π΅Ρ€Π΅Π· Ρ—Ρ— ΠΏΡ–Π΄Π²ΠΈΡ‰Π΅Π½Ρƒ Π»ΡƒΠΆΠ½Ρ–ΡΡ‚ΡŒ. Π ΠΎΠ·Ρ€ΠΎΠ±Π»Π΅Π½ΠΎ Π΅ΠΊΠΎΠ»ΠΎΠ³Ρ–Ρ‡Π½ΠΎ Π±Π΅Π·ΠΏΠ΅Ρ‡Π½Π΅ використання Ρ‚Π°ΠΊΠΈΡ… Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡ†Ρ–ΠΉΠ½ΠΈΡ… ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ–Π² Ρƒ Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΌΡƒ Ρ‚Π° Ρ€Ρ–Π΄ΠΊΠΎΠΌΡƒ стані як ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚Ρ–Π² Π±ΡƒΠ΄Ρ–Π²Π΅Π»ΡŒΠ½ΠΈΡ… ΠΌΠ°Ρ‚Π΅Ρ€Ρ–Π°Π»Ρ–Π². ΠΠ°ΠΉΠ±Ρ–Π»ΡŒΡˆ Π΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΈΠΌΠΈ Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΡƒΡŽΡ‡ΠΈΠΌΠΈ ΠΌΠ°Ρ‚Π΅Ρ€Ρ–Π°Π»Π°ΠΌΠΈ Ρ–Π· Π½Π°Π΄Ρ–ΠΉΠ½ΠΎΡŽ Ρ–ΠΌΠΌΠΎΠ±Ρ–Π»Ρ–Π·Π°Ρ†Ρ–ΡŽ сполук промислових Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π² Ρ” Π»ΡƒΠΆΠ½Ρ– в’яТучі Ρ€Π΅Ρ‡ΠΎΠ²ΠΈΠ½ΠΈ. Π’ Ρ€ΠΎΠ±ΠΎΡ‚Ρ– ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π½Ρ– Сксплуатаційні властивості Ρ‚Π°ΠΊΠΈΡ… ΠΌΠΎΠ΄ΠΈΡ„Ρ–ΠΊΠΎΠ²Π°Π½ΠΈΡ… Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Ρ–Π² Ρ‚Π° Π±Π΅Ρ‚ΠΎΠ½Ρ–Π² Π½Π° Ρ—Ρ… основі. ДослідТСно вилуговування Ρ–ΠΎΠ½Ρ–Π² Π²Π°ΠΆΠΊΠΈΡ… ΠΌΠ΅Ρ‚Π°Π»Ρ–Π² Ρ–Π· ΠΌΠ°Ρ‚Ρ€ΠΈΡ†Ρ– ΠΌΠ°Ρ‚Π΅Ρ€Ρ–Π°Π»Ρƒ Ρ‚Π° Π΄ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Ρ—Ρ… Π½Π°Π΄Ρ–ΠΉΠ½Ρƒ Ρ„Ρ–ΠΊΡΠ°Ρ†Ρ–ΡŽ Ρƒ структурі Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Ρ–Π². Завдяки Ρ†ΡŒΠΎΠΌΡƒ іммобілізація ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ–Π² водоочищСння Π² Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Π°Ρ… Ρ‚Π° Π±Π΅Ρ‚ΠΎΠ½Π°Ρ… Π½Π° Ρ—Ρ… основі Π½Π΅ ΠΏΠΎΠ³Ρ–Ρ€ΡˆΡƒΡ” ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠΈ Ρ—Ρ… Сксплуатаційних властивостСй Ρ– ΠΏΡ€ΠΈ Ρ†ΡŒΠΎΠΌΡƒ Π·Π°Π±Π΅Π·ΠΏΠ΅Ρ‡ΡƒΡ” ΠΏΠ΅Ρ€Π΅Π²Π°Π³ΠΈ Ρ‚Π°ΠΊΠΎΡ— ΡƒΡ‚ΠΈΠ»Ρ–Π·Π°Ρ†Ρ–Ρ— Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π².Π£ порівнянні Π· Π°Π½Π°Π»ΠΎΠ³Ρ–Ρ‡Π½ΠΈΠΌΠΈ Π²Ρ–Π΄ΠΎΠΌΠΈΠΌΠΈ тСхнологіями Ρ€ΠΎΠ·Ρ€ΠΎΠ±Π»Π΅Π½ΠΎ ΠΏΠΎΠ²Π½Ρ–ΡΡ‚ΡŽ Π±Π΅Π·Π²Ρ–Π΄Ρ…ΠΎΠ΄Π½Ρƒ комплСксну очистку промислових стоків Π³Π°Π»ΡŒΠ²Π°Π½Ρ–Ρ‡Π½ΠΈΡ… Π²ΠΈΡ€ΠΎΠ±Π½ΠΈΡ†Ρ‚Π² промислових підприємств

    Π ΠΎΠ·Ρ€ΠΎΠ±ΠΊΠ° Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³Ρ–Ρ— ΡƒΡ‚ΠΈΠ»Ρ–Π·Π°Ρ†Ρ–Ρ— ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ–Π² очистки промислових стоків ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ— Ρƒ ΠΌΠ°Ρ‚Ρ€ΠΈΡ†Ρ– Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Ρ–Π²

    Get PDF
    The object of research is liquid and solid wastes resulting from the processing of highly concentrated wastewater from industrial enterprises using the ferritization method. It is known that galvanic production creates large volumes of highly toxic waste requiring further processing or safe disposal. One of the most problematic places is the use of traditional reagent methods that do not provide high rates of treated water and chemical stability of a significant amount of solid-phase waste water.The use of ferritization technology allows eliminating the indicated disadvantages and increasing the efficiency of the industrial wastewater treatment process. In the course of the study, improved ferritization method with electromagnetic activation of the process is used, which can significantly increase its energy efficiency. However, dense and stable ferritization sediments that contain toxic compounds of heavy metals need reliable disposal. But even with proper treatment of wastewater from heavy metal compounds, they contain a large amount of other pollutants, making it impossible to discharge such water into natural water bodies, in particular, because of its increased alkalinity. Environmentally safe use of such substandard products in solid and liquid state as components of building materials is developed. The most effective cementing materials with reliable immobilization of industrial waste compounds are alkaline binders. The performance properties of such modified alkaline cements and concretes based on them are obtained. The leaching of heavy metal ions from the matrix of the material is investigated and their reliable fixation in the structure of alkaline cements is proved. Due to this, immobilization of water treatment products in alkaline cements and concretes based on them does not degrade the performance of their properties and at the same time provides the advantages of such waste disposal.Compared with similar known technologies, a completely waste-free complex treatment of industrial wastes of electroplating plants of industrial enterprises is developed.ΠžΠ±ΡŠΠ΅ΠΊΡ‚ΠΎΠΌ исслСдований ΡΠ²Π»ΡΡŽΡ‚ΡΡ ΠΆΠΈΠ΄ΠΊΠΈΠ΅ ΠΈ Ρ‚Π²Π΅Ρ€Π΄Ρ‹Π΅ ΠΎΡ‚Ρ…ΠΎΠ΄Ρ‹, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ Π² Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π΅ ΠΏΠ΅Ρ€Π΅Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ высококонцСнтрированных сточных Π²ΠΎΠ΄ ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… прСдприятий ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ. Π˜Π·Π²Π΅ΡΡ‚Π½ΠΎ, Ρ‡Ρ‚ΠΎ Π³Π°Π»ΡŒΠ²Π°Π½ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ производства производят большиС ΠΎΠ±ΡŠΠ΅ΠΌΡ‹ высокотоксичных ΠΎΡ‚Ρ…ΠΎΠ΄ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Ρ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ дальнСйшСй ΠΏΠ΅Ρ€Π΅Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ ΠΈΠ»ΠΈ бСзопасного захоронСния. Одним ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ½Ρ‹Ρ… мСст являСтся использованиС Ρ‚Ρ€Π°Π΄ΠΈΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… Ρ€Π΅Π°Π³Π΅Π½Ρ‚Π½Ρ‹Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Π½Π΅ ΠΎΠ±Π΅ΡΠΏΠ΅Ρ‡ΠΈΠ²Π°ΡŽΡ‚ высокиС ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ ΠΎΡ‡ΠΈΡ‰Π΅Π½Π½ΠΎΠΉ Π²ΠΎΠ΄Ρ‹ ΠΈ химичСской стойкости Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ количСства Ρ‚Π²Π΅Ρ€Π΄ΠΎΡ„Π°Π·ΠΎΠ²Ρ‹Ρ… ΠΎΡ‚Ρ…ΠΎΠ΄ΠΎΠ² водоочистки.ИспользованиС Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΉ Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ позволяСт ΠΈΠ·Π±Π΅ΠΆΠ°Ρ‚ΡŒ ΡƒΠΊΠ°Π·Π°Π½Π½Ρ‹Ρ… нСдостатков ΠΈ ΡƒΠ»ΡƒΡ‡ΡˆΠΈΡ‚ΡŒ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ процСсса ΠΏΠ΅Ρ€Π΅Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ сточных Π²ΠΎΠ΄. Π’ Ρ…ΠΎΠ΄Π΅ исслСдований использовали ΡƒΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½ΡΡ‚Π²ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ Π°Π²Ρ‚ΠΎΡ€Π°ΠΌΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ с элСктромагнитной Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠ΅ΠΉ процСсса, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΉ позволяСт сущСствСнно ΠΏΠΎΠ²Ρ‹ΡΠΈΡ‚ΡŒ Π΅Π³ΠΎ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ. Однако ΠΏΠ»ΠΎΡ‚Π½Ρ‹Π΅ ΠΈ стойкиС осадки Ρ„Π΅Ρ€Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†ΠΈΠΈ, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ содСрТат токсичныС соСдинСния тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ², Ρ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΡƒΡ‚ΠΈΠ»ΠΈΠ·Π°Ρ†ΠΈΠΈ. Но Π΄Π°ΠΆΠ΅ ΠΏΡ€ΠΈ Π½Π°Π΄Π»Π΅ΠΆΠ°Ρ‰Π΅ΠΉ очисткС сточных Π²ΠΎΠ΄ ΠΎΡ‚ соСдинСний тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ² ΠΎΠ½ΠΈ содСрТат большоС количСство Π΄Ρ€ΡƒΠ³ΠΈΡ… загрязнитСлСй, Ρ‡Ρ‚ΠΎ Π΄Π΅Π»Π°Π΅Ρ‚ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½Ρ‹ΠΌ сброс Ρ‚Π°ΠΊΠΎΠΉ Π²ΠΎΠ΄Ρ‹ Π² ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ‹Π΅ Π²ΠΎΠ΄ΠΎΠ΅ΠΌΡ‹, Π² частности, Π²Π²ΠΈΠ΄Ρƒ Π΅Π΅ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½ΠΎΠΉ щСлочности. Π Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Π° экологичСски бСзопасная тСхнология использования Ρ‚Π°ΠΊΠΈΡ… Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² Π² Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΌ ΠΈ ΠΆΠΈΠ΄ΠΊΠΎΠΌ состоянии ΠΊΠ°ΠΊ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² ΡΡ‚Ρ€ΠΎΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΠΎΠ². НаиболСС эффСктивными Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠΌΠΈ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π°ΠΌΠΈ с Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠΉ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ соСдинСний тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ² ΡΠ²Π»ΡΡŽΡ‚ΡΡ Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Π΅ вяТущиС вСщСства. Π’ Ρ€Π°Π±ΠΎΡ‚Π΅ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ эксплуатационныС свойства Ρ‚Π°ΠΊΠΈΡ… ΠΌΠΎΠ΄ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Ρ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΠΎΠ² ΠΈ Π±Π΅Ρ‚ΠΎΠ½ΠΎΠ² Π½Π° ΠΈΡ… основС. ИсслСдовано Π²Ρ‹Ρ‰Π΅Π»Π°Ρ‡ΠΈΠ²Π°Π½ΠΈΠ΅ ΠΈΠΎΠ½ΠΎΠ² тяТСлых ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠ² ΠΈΠ· ΠΌΠ°Ρ‚Ρ€ΠΈΡ†Ρ‹ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π° ΠΈ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° ΠΈΡ… надСТная фиксация Π² структурС Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Ρ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΠΎΠ². Благодаря этому иммобилизация ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚ΠΎΠ² водоочистки Π² Ρ‰Π΅Π»ΠΎΡ‡Π½Ρ‹Ρ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Π°Ρ… ΠΈ Π±Π΅Ρ‚ΠΎΠ½Π°Ρ… Π½Π° ΠΈΡ… основС Π½Π΅ ΡƒΡ…ΡƒΠ΄ΡˆΠ°Π΅Ρ‚ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ ΠΈΡ… эксплуатационных свойств ΠΈ ΠΏΡ€ΠΈ этом обСспСчиваСт прСимущСства Ρ‚Π°ΠΊΠΎΠΉ ΡƒΡ‚ΠΈΠ»ΠΈΠ·Π°Ρ†ΠΈΠΈ ΠΎΡ‚Ρ…ΠΎΠ΄ΠΎΠ².Π’ сравнСнии с Π°Π½Π°Π»ΠΎΠ³ΠΈΡ‡Π½Ρ‹ΠΌΠΈ извСстными тСхнологиями Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Π° ΠΏΠΎΠ»Π½ΠΎΡΡ‚ΡŒΡŽ бСзотходная тСхнология комплСксной очистки ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… стоков Π³Π°Π»ΡŒΠ²Π°Π½ΠΈΡ‡Π΅ΡΠΊΠΈΡ… производств ΠΏΡ€ΠΎΠΌΡ‹ΡˆΠ»Π΅Π½Π½Ρ‹Ρ… прСдприятий.Об'Ρ”ΠΊΡ‚ΠΎΠΌ дослідТСння Ρ” Ρ€Ρ–Π΄ΠΊΡ– Ρ‚Π° Ρ‚Π²Π΅Ρ€Π΄Ρ– Π²Ρ–Π΄Ρ…ΠΎΠ΄ΠΈ, які ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π½Ρ– Π² Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ– ΠΏΠ΅Ρ€Π΅Ρ€ΠΎΠ±ΠΊΠΈ висококонцСнтрованих стічних Π²ΠΎΠ΄ промислових підприємств ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ—. Π’Ρ–Π΄ΠΎΠΌΠΎ, Ρ‰ΠΎ Π³Π°Π»ΡŒΠ²Π°Π½Ρ–Ρ‡Π½Ρ– Π²ΠΈΡ€ΠΎΠ±Π½ΠΈΡ†Ρ‚Π²Π° ΡΡ‚Π²ΠΎΡ€ΡŽΡŽΡ‚ΡŒ Π²Π΅Π»ΠΈΠΊΡ– об’єми високотоксичних Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π², які ΠΏΠΎΡ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ΡŒ ΠΏΠΎΠ΄Π°Π»ΡŒΡˆΠΎΡ— ΠΏΠ΅Ρ€Π΅Ρ€ΠΎΠ±ΠΊΠΈ Π°Π±ΠΎ Π±Π΅Π·ΠΏΠ΅Ρ‡Π½ΠΎΠ³ΠΎ захоронСння. Одним Π· Π½Π°ΠΉΠ±Ρ–Π»ΡŒΡˆ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ½ΠΈΡ… ΠΌΡ–ΡΡ†ΡŒ Ρ” застосування Ρ‚Ρ€Π°Π΄ΠΈΡ†Ρ–ΠΉΠ½ΠΈΡ… Ρ€Π΅Π°Π³Π΅Π½Ρ‚Π½ΠΈΡ… ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ–Π², які Π½Π΅ Π·Π°Π±Π΅Π·ΠΏΠ΅Ρ‡ΡƒΡŽΡ‚ΡŒ високих ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡ–Π² ΠΎΡ‡ΠΈΡ‰Π΅Π½ΠΎΡ— Π²ΠΎΠ΄ΠΈ Ρ‚Π° Ρ…Ρ–ΠΌΡ–Ρ‡Π½ΠΎΡ— стійкості Π·Π½Π°Ρ‡Π½ΠΎΡ— ΠΊΡ–Π»ΡŒΠΊΠΎΡΡ‚Ρ– Ρ‚Π²Π΅Ρ€Π΄ΠΎΡ„Π°Π·Π½ΠΈΡ… Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π² водоочищСння.Використання Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–ΠΉΠ½ΠΎΡ— Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³Ρ–Ρ— дозволяє усунути Π·Π°Π·Π½Π°Ρ‡Π΅Π½Ρ– Π½Π΅Π΄ΠΎΠ»Ρ–ΠΊΠΈ Ρ‚Π° ΠΏΠΎΠΊΡ€Π°Ρ‰ΠΈΡ‚ΠΈ Π΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡΡ‚ΡŒ процСсу ΠΏΠ΅Ρ€Π΅Ρ€ΠΎΠ±ΠΊΠΈ промислових стічних Π²ΠΎΠ΄. Π’ Ρ…ΠΎΠ΄Ρ– дослідТСння використовувалися удосконалСний Π°Π²Ρ‚ΠΎΡ€Π°ΠΌΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ— Ρ–Π· Π΅Π»Π΅ΠΊΡ‚Ρ€ΠΎΠΌΠ°Π³Π½Ρ–Ρ‚Π½ΠΎΡŽ Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†Ρ–Ρ”ΡŽ процСсу, Ρ‰ΠΎ дозволяє суттєво ΠΏΡ–Π΄Π²ΠΈΡ‰ΠΈΡ‚ΠΈ ΠΉΠΎΠ³ΠΎ Π΅Π½Π΅Ρ€Π³ΠΎΠ΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡΡ‚ΡŒ. ΠŸΡ€ΠΎΡ‚Π΅ Ρ‰Ρ–Π»ΡŒΠ½Ρ– Ρ– стійкі осади Ρ„Π΅Ρ€ΠΈΡ‚ΠΈΠ·Π°Ρ†Ρ–Ρ—, які ΠΌΡ–ΡΡ‚ΡΡ‚ΡŒ токсичні сполуки Π²Π°ΠΆΠΊΠΈΡ… ΠΌΠ΅Ρ‚Π°Π»Ρ–Π², ΠΏΠΎΡ‚Ρ€Π΅Π±ΡƒΡŽΡ‚ΡŒ Π½Π°Π΄Ρ–ΠΉΠ½ΠΎΡ— ΡƒΡ‚ΠΈΠ»Ρ–Π·Π°Ρ†Ρ–Ρ—. АлС Π½Π°Π²Ρ–Ρ‚ΡŒ ΠΏΡ€ΠΈ Π½Π°Π»Π΅ΠΆΠ½ΠΎΠΌΡƒ ΠΎΡ‡ΠΈΡ‰Π΅Π½Π½Ρ– стічних Π²ΠΎΠ΄ Π²Ρ–Π΄ сполук Π²Π°ΠΆΠΊΠΈΡ… ΠΌΠ΅Ρ‚Π°Π»Ρ–Π², Π²ΠΎΠ½ΠΈ ΠΌΡ–ΡΡ‚ΡΡ‚ΡŒ Π²Π΅Π»ΠΈΠΊΡƒ ΠΊΡ–Π»ΡŒΠΊΡ–ΡΡ‚ΡŒ Ρ–Π½ΡˆΠΈΡ… Π·Π°Π±Ρ€ΡƒΠ΄Π½ΡŽΠ²Π°Ρ‡Ρ–Π², Ρ‰ΠΎ ΡƒΠ½Π΅ΠΌΠΎΠΆΠ»ΠΈΠ²Π»ΡŽΡ” скидання Ρ‚Π°ΠΊΠΎΡ— Π²ΠΎΠ΄ΠΈ Ρƒ ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ– Π²ΠΎΠ΄ΠΎΠΉΠΌΠΈ, Π·ΠΎΠΊΡ€Π΅ΠΌΠ°, Ρ‡Π΅Ρ€Π΅Π· Ρ—Ρ— ΠΏΡ–Π΄Π²ΠΈΡ‰Π΅Π½Ρƒ Π»ΡƒΠΆΠ½Ρ–ΡΡ‚ΡŒ. Π ΠΎΠ·Ρ€ΠΎΠ±Π»Π΅Π½ΠΎ Π΅ΠΊΠΎΠ»ΠΎΠ³Ρ–Ρ‡Π½ΠΎ Π±Π΅Π·ΠΏΠ΅Ρ‡Π½Π΅ використання Ρ‚Π°ΠΊΠΈΡ… Π½Π΅ΠΊΠΎΠ½Π΄ΠΈΡ†Ρ–ΠΉΠ½ΠΈΡ… ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ–Π² Ρƒ Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΌΡƒ Ρ‚Π° Ρ€Ρ–Π΄ΠΊΠΎΠΌΡƒ стані як ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚Ρ–Π² Π±ΡƒΠ΄Ρ–Π²Π΅Π»ΡŒΠ½ΠΈΡ… ΠΌΠ°Ρ‚Π΅Ρ€Ρ–Π°Π»Ρ–Π². ΠΠ°ΠΉΠ±Ρ–Π»ΡŒΡˆ Π΅Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΈΠΌΠΈ Ρ†Π΅ΠΌΠ΅Π½Ρ‚ΡƒΡŽΡ‡ΠΈΠΌΠΈ ΠΌΠ°Ρ‚Π΅Ρ€Ρ–Π°Π»Π°ΠΌΠΈ Ρ–Π· Π½Π°Π΄Ρ–ΠΉΠ½ΠΎΡŽ Ρ–ΠΌΠΌΠΎΠ±Ρ–Π»Ρ–Π·Π°Ρ†Ρ–ΡŽ сполук промислових Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π² Ρ” Π»ΡƒΠΆΠ½Ρ– в’яТучі Ρ€Π΅Ρ‡ΠΎΠ²ΠΈΠ½ΠΈ. Π’ Ρ€ΠΎΠ±ΠΎΡ‚Ρ– ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π½Ρ– Сксплуатаційні властивості Ρ‚Π°ΠΊΠΈΡ… ΠΌΠΎΠ΄ΠΈΡ„Ρ–ΠΊΠΎΠ²Π°Π½ΠΈΡ… Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Ρ–Π² Ρ‚Π° Π±Π΅Ρ‚ΠΎΠ½Ρ–Π² Π½Π° Ρ—Ρ… основі. ДослідТСно вилуговування Ρ–ΠΎΠ½Ρ–Π² Π²Π°ΠΆΠΊΠΈΡ… ΠΌΠ΅Ρ‚Π°Π»Ρ–Π² Ρ–Π· ΠΌΠ°Ρ‚Ρ€ΠΈΡ†Ρ– ΠΌΠ°Ρ‚Π΅Ρ€Ρ–Π°Π»Ρƒ Ρ‚Π° Π΄ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Ρ—Ρ… Π½Π°Π΄Ρ–ΠΉΠ½Ρƒ Ρ„Ρ–ΠΊΡΠ°Ρ†Ρ–ΡŽ Ρƒ структурі Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Ρ–Π². Завдяки Ρ†ΡŒΠΎΠΌΡƒ іммобілізація ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Ρ–Π² водоочищСння Π² Π»ΡƒΠΆΠ½ΠΈΡ… Ρ†Π΅ΠΌΠ΅Π½Ρ‚Π°Ρ… Ρ‚Π° Π±Π΅Ρ‚ΠΎΠ½Π°Ρ… Π½Π° Ρ—Ρ… основі Π½Π΅ ΠΏΠΎΠ³Ρ–Ρ€ΡˆΡƒΡ” ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΠΈ Ρ—Ρ… Сксплуатаційних властивостСй Ρ– ΠΏΡ€ΠΈ Ρ†ΡŒΠΎΠΌΡƒ Π·Π°Π±Π΅Π·ΠΏΠ΅Ρ‡ΡƒΡ” ΠΏΠ΅Ρ€Π΅Π²Π°Π³ΠΈ Ρ‚Π°ΠΊΠΎΡ— ΡƒΡ‚ΠΈΠ»Ρ–Π·Π°Ρ†Ρ–Ρ— Π²Ρ–Π΄Ρ…ΠΎΠ΄Ρ–Π².Π£ порівнянні Π· Π°Π½Π°Π»ΠΎΠ³Ρ–Ρ‡Π½ΠΈΠΌΠΈ Π²Ρ–Π΄ΠΎΠΌΠΈΠΌΠΈ тСхнологіями Ρ€ΠΎΠ·Ρ€ΠΎΠ±Π»Π΅Π½ΠΎ ΠΏΠΎΠ²Π½Ρ–ΡΡ‚ΡŽ Π±Π΅Π·Π²Ρ–Π΄Ρ…ΠΎΠ΄Π½Ρƒ комплСксну очистку промислових стоків Π³Π°Π»ΡŒΠ²Π°Π½Ρ–Ρ‡Π½ΠΈΡ… Π²ΠΈΡ€ΠΎΠ±Π½ΠΈΡ†Ρ‚Π² промислових підприємств

    SPARC-like 1 Regulates the Terminal Phase of Radial Glia-Guided Migration in the Cerebral Cortex

    Get PDF
    Differential adhesion between migrating neurons and transient radial glial fibers enables the deployment of neurons into appropriate layers in the developing cerebral cortex. The identity of radial glial signals that regulate the termination of migration remains unclear. Here, we identified a radial glial surface antigen, SPARC (secreted protein acidic and rich in cysteine)-like 1, distributed predominantly in radial glial fibers passing through the upper strata of the cortical plate (CP) where neurons end their migration. Neuronal migration and adhesion assays indicate that SPARC-like 1 functions to terminate neuronal migration by reducing the adhesivity of neurons at the top of the CP. Cortical neurons fail to achieve appropriate positions in the absence of SPARC-like 1 function in vivo. Together, these data suggest that antiadhesive signaling via SPARC-like 1 on radial glial cell surfaces may enable neurons to recognize the end of migration in the developing cerebral cortex

    γ‚ͺンガクゲキ ヒョウゲン カテむ ニγ‚ͺケル ガむテキ γƒŠγ‚€γƒ†γ‚­ ケむショウ γƒŽ γ‚€γƒŸ : γ‚ͺンガクゲキ キャクホン ツタカズラ γ‚³γƒžγƒγƒ‡γƒ³ γ‚ͺ ジレむ γƒˆγ‚·γƒ†

    Get PDF
    The purpose of this paper is to consider the meaning of external, internal images in the process of expression on music drama. The major results of this consideration can be summarized as follows: The external image is the "form" of reality, embodiment, that is to say, something visible and audible. On the other hand, the internal image is the simbolic form of idea, imagination, visions, enviromental factor, affect (i. e. substance of consciousness, etc.), that is to say, samething invisible. And the expression in the Music Drama is itself the mental act of representing subject subsisted in emotion and reality from expression, such as singing, acting and the theatrical line, etc..ε›½η«‹ζƒ…ε ±ε­¦η ”η©Άζ‰€γ€Žη ”η©Άη΄€θ¦ε…¬ι–‹ζ”―ζ΄δΊ‹ζ₯­γ€γ«γ‚ˆγ‚Šι›»ε­εŒ–

    Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    Get PDF
    Background: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. Methods: We nested a two-period, fixed-order pharmacokinetic substudy within the open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres in South Africa, Uganda, and Zimbabwe. Children (aged 4 weeks to <18 years) with HIV-associated TB who were receiving rifampicin and twice-daily dolutegravir were eligible for inclusion. We did a 12-h pharmacokinetic profile on rifampicin and twice-daily dolutegravir and a 24-h profile on once-daily dolutegravir. Geometric mean ratios for trough plasma concentration (Ctrough), area under the plasma concentration time curve from 0 h to 24 h after dosing (AUC0–24 h), and maximum plasma concentration (Cmax) were used to compare dolutegravir concentrations between substudy days. We assessed rifampicin Cmax on the first substudy day. All children within ODYSSEY with HIV-associated TB who received rifampicin and twice-daily dolutegravir were included in the safety analysis. We described adverse events reported from starting twice-daily dolutegravir to 30 days after returning to once-daily dolutegravir. This trial is registered with ClinicalTrials.gov (NCT02259127), EudraCT (2014–002632-14), and the ISRCTN registry (ISRCTN91737921). Findings: Between Sept 20, 2016, and June 28, 2021, 37 children with HIV-associated TB (median age 11Β·9 years [range 0Β·4–17Β·6], 19 [51%] were female and 18 [49%] were male, 36 [97%] in Africa and one [3%] in Thailand) received rifampicin with twice-daily dolutegravir and were included in the safety analysis. 20 (54%) of 37 children enrolled in the pharmacokinetic substudy, 14 of whom contributed at least one evaluable pharmacokinetic curve for dolutegravir, including 12 who had within-participant comparisons. Geometric mean ratios for rifampicin and twice-daily dolutegravir versus once-daily dolutegravir were 1Β·51 (90% CI 1Β·08–2Β·11) for Ctrough, 1Β·23 (0Β·99–1Β·53) for AUC0–24 h, and 0Β·94 (0Β·76–1Β·16) for Cmax. Individual dolutegravir Ctrough concentrations were higher than the 90% effective concentration (ie, 0Β·32 mg/L) in all children receiving rifampicin and twice-daily dolutegravir. Of 18 children with evaluable rifampicin concentrations, 15 (83%) had a Cmax of less than the optimal target concentration of 8 mg/L. Rifampicin geometric mean Cmax was 5Β·1 mg/L (coefficient of variation 71%). During a median follow-up of 31 weeks (IQR 30–40), 15 grade 3 or higher adverse events occurred among 11 (30%) of 37 children, ten serious adverse events occurred among eight (22%) children, including two deaths (one tuberculosis-related death, one death due to traumatic injury); no adverse events, including deaths, were considered related to dolutegravir. Interpretation: Twice-daily dolutegravir was shown to be safe and sufficient to overcome the rifampicin enzyme-inducing effect in children, and could provide a practical ART option for children with HIV-associated TB

    Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    Get PDF
    BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus alternative antiretroviral therapy. METHODS: This is a secondary analysis of ODYSSEY, an open-label, multicentre, randomised, non-inferiority trial, in which adolescents and children initiating first-line or second-line antiretroviral therapy were randomly assigned 1:1 to dolutegravir-based treatment or standard-of-care treatment. We assessed neuropsychiatric adverse events (reported by clinicians) and responses to the mood and sleep questionnaires (reported by the participant or their carer) in both groups. We compared the proportions of patients with neuropsychiatric adverse events (neurological, psychiatric, and total), time to first neuropsychiatric adverse event, and participant-reported responses to questionnaires capturing issues with mood, suicidal thoughts, and sleep problems. FINDINGS: Between Sept 20, 2016, and June 22, 2018, 707 participants were enrolled, of whom 345 (49%) were female and 362 (51%) were male, and 623 (88%) were Black-African. Of 707 participants, 350 (50%) were randomly assigned to dolutegravir-based antiretroviral therapy and 357 (50%) to non-dolutegravir-based standard-of-care. 311 (44%) of 707 participants started first-line antiretroviral therapy (ODYSSEY-A; 145 [92%] of 157 participants had efavirenz-based therapy in the standard-of-care group), and 396 (56%) of 707 started second-line therapy (ODYSSEY-B; 195 [98%] of 200 had protease inhibitor-based therapy in the standard-of-care group). During follow-up (median 142 weeks, IQR 124–159), 23 participants had 31 neuropsychiatric adverse events (15 in the dolutegravir group and eight in the standard-of-care group; difference in proportion of participants with β‰₯1 event p=0Β·13). 11 participants had one or more neurological events (six and five; p=0Β·74) and 14 participants had one or more psychiatric events (ten and four; p=0Β·097). Among 14 participants with psychiatric events, eight participants in the dolutegravir group and four in standard-of-care group had suicidal ideation or behaviour. More participants in the dolutegravir group than the standard-of-care group reported symptoms of self-harm (eight vs one; p=0Β·025), life not worth living (17 vs five; p=0Β·0091), or suicidal thoughts (13 vs none; p=0Β·0006) at one or more follow-up visits. Most reports were transient. There were no differences by treatment group in low mood or feeling sad, problems concentrating, feeling worried or feeling angry or aggressive, sleep problems, or sleep quality. INTERPRETATION: The numbers of neuropsychiatric adverse events and reported neuropsychiatric symptoms were low. However, numerically more participants had psychiatric events and reported suicidality ideation in the dolutegravir group than the standard-of-care group. These differences should be interpreted with caution in an open-label trial. Clinicians and policy makers should consider including suicidality screening of children or adolescents receiving dolutegravir

    Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

    Get PDF

    Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels

    Get PDF
    Leptin is an adipocyte-secreted hormone, the circulating levels of which correlate closely with overall adiposity. Although rare mutations in the leptin (LEP) gene are well known to cause leptin deficiency and severe obesity, no common loci regulating circulating leptin levels have been uncovered. Therefore, we performed a genome-wide association study (GWAS) of circulating leptin levels from 32,161 individuals and followed up loci reaching P <10(-6) in 19,979 additional individuals. We identify five loci robustly associated (P <5 x 10(-8)) with leptin levels in/near LEP, SLC32A1, GCKR, CCNL1 and FTO. Although the association of the FTO obesity locus with leptin levels is abolished by adjustment for BMI, associations of the four other loci are independent of adiposity. The GCKR locus was found associated with multiple metabolic traits in previous GWAS and the CCNL1 locus with birth weight. Knockdown experiments in mouse adipose tissue explants show convincing evidence for adipogenin, a regulator of adipocyte differentiation, as the novel causal gene in the SLC32A1 locus influencing leptin levels. Our findings provide novel insights into the regulation of leptin production by adipose tissue and open new avenues for examining the influence of variation in leptin levels on adiposity and metabolic health.Peer reviewe
    corecore